Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | NQO1 | P15559 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NCEH1 | Q6PIU2 | 3/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8838377 | 0.86 | MAPT (0.60) | MAPTHCRTR1PLAUNQO1KDM4E | |
| SCHEMBL28727034 | 0.83 | ALDH1A1 (0.47) | MAPTHCRTR1KMT2AMEN1NCEH1 | |
| Iodide SCHEMBL25364438 | 0.80 | MAPT (0.53) | MAPTHCRTR1NQO1KDM4EHPGD | |
| SCHEMBL23515216 | 0.80 | HTR1B (0.51) | MAPTKDM4E | |
| SCHEMBL4594510 | 0.80 | MAPT (0.54) | MAPTKDM4EHPGDPOLBKMT2A | |
| SCHEMBL4594512 | 0.79 | POLB (0.52) | HCRTR1KDM4EHPGDPOLBKMT2A | |
| SCHEMBL23499928 | 0.79 | MTNR1A (0.56) | MAPTHCRTR1KDM4EHPGDMTNR1A | |
| SCHEMBL8336311 | 0.79 | MAPT (0.51) | MAPTHCRTR1PLAUNQO1KDM4E | |
| SCHEMBL7369757 | 0.79 | MAPT (0.51) | MAPTHCRTR1KDM4EHPGDMTNR1A | |
| SCHEMBL998182 | 0.77 | MAPT (1.00) | MAPTNQO1KDM4EHPGDMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255232-A1 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-10-16 | — | — | US | claimed |
| EP-1937243-A2 | NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2008-07-02 | — | — | EP | claimed |
| WO-2007045593-A2 | NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-04-26 | — | — | WO | claimed |
| CN-114401935-B | Ion channel antagonists/blockers and uses thereof | 上海市东方医院（同济大学附属东方医院） | 2024-04-05 | — | — | CN | disclosed |
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | SHANGHAI EAST HOSPITAL (CN) | 2023-01-19 | — | — | US | disclosed |
| CN-114401935-A | Ion channel antagonists/blockers and uses thereof | 上海市东方医院（同济大学附属东方医院） | 2022-04-26 | — | — | CN | disclosed |
| WO-2021114313-A1 | ION CHANNEL ANTAGONISTS/BLOCKERS AND USES THEREOF | SHANGHAI EAST HOSPITAL (CN) | 2021-06-17 | — | — | WO | disclosed |
| US-20080255232-A1 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-10-16 | — | — | US | disclosed |
| US-20080255232-A1 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-10-16 | — | — | US | disclosed |
| US-20080255232-A1 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-10-16 | — | — | US | disclosed |
| EP-1937243-A2 | NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007045593-A2 | NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045593-A2 | NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | CACNA1F, CACNA1S, CACNA1D | MAPT 2678/4885HCRTR1 1640/4885PLAU 3058/4885 |
| US-20080255232-A1 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation | APP, BACE1, SNCA | MAPT 9/4885HCRTR1 1882/4885PLAU 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.